/
COMPANY OVERVIEW We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, …
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$249M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$327M
▼ -65.9% YoY
Op. Margin
—
ROIC
-37.16%
▲ +22.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$282M
▼ -89.1% YoY
Op. Cash Flow (TTM)
-$282M
▼ -89.0% YoY
Net Debt
-$785M
Net Cash Position
Cash & Equiv.
$787M
Continue Research